Global Hypercholesterolemia Market By Diagnosis (Blood Tests, Cholesterol Tests, Genetic Testing, Cardiac Stress test or an echocardiogram); By Business Model (B2B, B2C); By Treatment (Stains, Bile acid sequestrant resins, Ezetimibe, Nicotonic acid, or niacin, Gemfibrozil, Fenofibrate, Lovastatin (Mevacor), Pravastatin (Pravachol), Simvastatin (Zocor), Fluvastatin (Lescol), Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Hypercholesterolemia happens to be a medical condition that is related with high levels of blood cholesterol. Cholesterol primarily is a substance that is waxy in nature and is produced by the liver and happens to be component of majority of cells found in the human body. Total cholesterol needed by a human is made by the liver, though another source happens to be the dietary cholesterol that is derived from animal food products like meat, dairy, poultry, fish and egg yolk. These kinds of foods are enriched with saturated fats and trans fats that are capable of triggering the liver to create additional cholesterol, which further leads to hypercholesterolemia.
The primary function of cholesterol is synthesis of cell membranes along with certain hormones and producing substances needed for the digestion of fat. Meanwhile, higher levels of cholesterol are likely to increase the risk of coronary artery disease. When it comes to hypercholesterolemia, one needs to understand what really leads to it. Excess accumulation of the cholesterol in several bodily tissues like tendons is one sign of this medical condition. Higher amounts of cholesterol present in the one’s blood creates fatty deposits in the walls of the coronary arteries. Following accumulation of the cholesterol, athereosclerosis plaques are formed and this is what narrows and solidifies the walls of arteries. Over the period of time, such plaques are likely to block the arteries and curb the amount of oxygen in the blood that is capable of reaching the blood-pumping machine. All these conditions can create severe heart problems like heart attack. All this is driving the growth of the global hypercholesterolemia market.
In terms of revenue, global hypercholesterolemia market was valued at US$ 12.95 Bn in 2021 growing at a CAGR of 15.7% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Hypercholesterolemia Market Revenue & Forecast, (US$ Million), 2015 – 2030
Diagnosis Outlook
Based on the diagnosis outlook, the global hypercholesterolemia market has been segmented into blood tests, cholesterol tests, genetic testing and cardiac stress test or an echocardiogram. The genetic testing segment accounts for majority of revenue generated by this market. It use to extremely difficult to diagnose this medical condition as it does not generally showcase any type of symptoms. This is why, the only effective way to diagnose whether one is having hypercholesterolemia is by performing check of the cholesterol levels in the blood, which is called lipid profile. The lipid profile tests are inclusive of total cholesterol, LDL cholesterol, HDL cholesterol along with the levels of triglyceride. Meanwhile, it has been observed that this medical condition can be genetic and this is why the genetic testing proves extremely helpful. Hence majority of medical experts are turning towards this type of testing.
Region Outlook
Based on region North America accounts for most of the money made by the global hypercholesterolemia market in the year 2021. Over the period of last couple of decades, it has been observed that majority of people, especially those aging below 40 in countries like the United States and Canada are suffering from obesity. Deteriorating life style, consumption of junk food and alcohol, along with lack of exercise is the reason most of the people are seeing the medical condition of hypercholesterolemia. Growing adverse impact of various factors are also contributing to the growth of this market. On the other hand, several new pharmaceutical companies are turning towards seeking the solution for this medical condition or help in the preventing this condition.
Competitive Landscape
The report provides both, qualitative and quantitative research of global hypercholesterolemia market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global hypercholesterolemia market are:
- Aegerion Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Amarin Pharmaceuticals, Inc.
- Amgen Inc.
- AstraZeneca
- Eli Lily and Company
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Sanofi
- Tekmira Pharmaceuticals Corporation
- Valbiotis
- Verve Therapeutics, Inc.
- Other Industry Participants
Global Hypercholesterolemia Market:
By Diagnosis
- Blood Tests
- Cholesterol Tests
- Genetic Testing
- Cardiac stress test or an echocardiogram
By Treatment
- Stains
- Bile acid sequestrant resins
- Ezetimibe
- Nicotinic acid, or niacin
- Gemfibrozil
- Fenofibrate
- Lovastatin (Mevacor)
- Pravastatin (Pravachol)
- Simvastatin (Zocor)
- Fluvastatin (Lescol)
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 - 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Hypercholesterolemia Market
6. Market Synopsis:
Hypercholesterolemia Market
7. Hypercholesterolemia Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Hypercholesterolemia Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Hypercholesterolemia Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of Covid-19
on Hypercholesterolemia Market
8. Global Hypercholesterolemia Market Analysis and Forecasts, 2022
- 2030
8.1. Overview
8.1.1. Global
Hypercholesterolemia Market Revenue (US$ Mn)
8.2. Global
Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By Diagnosis
8.2.1. Blood
Tests
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2021
8.2.1.3. Market Forecast, 2022 - 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. Cholesterol Tests
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 - 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.2.3. Genetic
Testing
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2021
8.2.3.3. Market Forecast, 2022 - 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 - 2030
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 - 2030
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 - 2030
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 - 2030
8.2.4. Cardiac
stress test or an echocardiogram
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2021
8.2.4.3. Market Forecast, 2022 - 2030
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 - 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 - 2030
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 - 2030
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 - 2030
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By
Diagnosis
9. Global Hypercholesterolemia Market Analysis and Forecasts, 2022
- 2030
9.1. Overview
9.2. Global
Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By Treatment
9.2.1. Stains
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2. Bile
acid sequestrant resins
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.2.3. Ezetimibe
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2021
9.2.3.3. Market Forecast, 2022 - 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 - 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 - 2030
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 - 2030
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 - 2030
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 - 2030
9.2.4. Nicotinic
acid, or niacin
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 - 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 - 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 - 2030
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 - 2030
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 - 2030
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 - 2030
9.2.5. Gemfibrozil
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 - 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 - 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 - 2030
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 - 2030
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 - 2030
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 - 2030
9.2.6. Fenofibrate
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2021
9.2.6.3. Market Forecast, 2022 - 2030
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2021
9.2.6.5.1.2. Market Forecast, 2022 - 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2021
9.2.6.5.2.2. Market Forecast, 2022 - 2030
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2021
9.2.6.5.3.2. Market Forecast, 2022 - 2030
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2021
9.2.6.5.4.2. Market Forecast, 2022 - 2030
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2021
9.2.6.5.5.2. Market Forecast, 2022 - 2030
9.2.7. Lovastatin
(Mevacor)
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2021
9.2.7.3. Market Forecast, 2022 - 2030
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North
America
9.2.7.5.1.1. Market Estimation, 2015 - 2021
9.2.7.5.1.2. Market Forecast, 2022 - 2030
9.2.7.5.2. Europe
9.2.7.5.2.1. Market Estimation, 2015 - 2021
9.2.7.5.2.2. Market Forecast, 2022 - 2030
9.2.7.5.3. Asia
Pacific
9.2.7.5.3.1. Market Estimation, 2015 - 2021
9.2.7.5.3.2. Market Forecast, 2022 - 2030
9.2.7.5.4. Middle
East and Africa
9.2.7.5.4.1. Market Estimation, 2015 - 2021
9.2.7.5.4.2. Market Forecast, 2022 - 2030
9.2.7.5.5. Latin
America
9.2.7.5.5.1. Market Estimation, 2015 - 2021
9.2.7.5.5.2. Market Forecast, 2022 - 2030
9.2.8. Pravastatin
(Pravachol)
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2015 - 2021
9.2.8.3. Market Forecast, 2022 - 2030
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North
America
9.2.8.5.1.1. Market Estimation, 2015 - 2021
9.2.8.5.1.2. Market Forecast, 2022 - 2030
9.2.8.5.2. Europe
9.2.8.5.2.1. Market Estimation, 2015 - 2021
9.2.8.5.2.2. Market Forecast, 2022 - 2030
9.2.8.5.3. Asia
Pacific
9.2.8.5.3.1. Market Estimation, 2015 - 2021
9.2.8.5.3.2. Market Forecast, 2022 - 2030
9.2.8.5.4. Middle
East and Africa
9.2.8.5.4.1. Market Estimation, 2015 - 2021
9.2.8.5.4.2. Market Forecast, 2022 - 2030
9.2.8.5.5. Latin
America
9.2.8.5.5.1. Market Estimation, 2015 - 2021
9.2.8.5.5.2. Market Forecast, 2022 - 2030
9.2.9. Simvastatin (Zocor)
9.2.9.1. Definition
9.2.9.2. Market Estimation and Penetration, 2015 - 2021
9.2.9.3. Market Forecast, 2022 - 2030
9.2.9.4. Compound Annual Growth Rate (CAGR)
9.2.9.5. Regional Bifurcation
9.2.9.5.1. North
America
9.2.9.5.1.1. Market Estimation, 2015 - 2021
9.2.9.5.1.2. Market Forecast, 2022 - 2030
9.2.9.5.2. Europe
9.2.9.5.2.1. Market Estimation, 2015 - 2021
9.2.9.5.2.2. Market Forecast, 2022 - 2030
9.2.9.5.3. Asia
Pacific
9.2.9.5.3.1. Market Estimation, 2015 - 2021
9.2.9.5.3.2. Market Forecast, 2022 - 2030
9.2.9.5.4. Middle
East and Africa
9.2.9.5.4.1. Market Estimation, 2015 - 2021
9.2.9.5.4.2. Market Forecast, 2022 - 2030
9.2.9.5.5. Latin
America
9.2.9.5.5.1. Market Estimation, 2015 - 2021
9.2.9.5.5.2. Market Forecast, 2022 - 2030
9.2.10. Fluvastatin
(Lescol)
9.2.10.1. Definition
9.2.10.2. Market Estimation and Penetration, 2015 - 2021
9.2.10.3. Market Forecast, 2022 - 2030
9.2.10.4. Compound Annual Growth Rate (CAGR)
9.2.10.5. Regional Bifurcation
9.2.10.5.1. North
America
9.2.10.5.1.1.
Market Estimation, 2015 - 2021
9.2.10.5.1.2.
Market Forecast, 2022 - 2030
9.2.10.5.2. Europe
9.2.10.5.2.1.
Market Estimation, 2015 - 2021
9.2.10.5.2.2.
Market Forecast, 2022 - 2030
9.2.10.5.3. Asia
Pacific
9.2.10.5.3.1.
Market Estimation, 2015 - 2021
9.2.10.5.3.2.
Market Forecast, 2022 - 2030
9.2.10.5.4. Middle
East and Africa
9.2.10.5.4.1.
Market Estimation, 2015 - 2021
9.2.10.5.4.2.
Market Forecast, 2022 - 2030
9.2.10.5.5. Latin
America
9.2.10.5.5.1.
Market Estimation, 2015 - 2021
9.2.10.5.5.2.
Market Forecast, 2022 - 2030
9.2.11. Others
9.2.11.1. Definition
9.2.11.2. Market Estimation and Penetration, 2015 - 2021
9.2.11.3. Market Forecast, 2022 - 2030
9.2.11.4. Compound Annual Growth Rate (CAGR)
9.2.11.5. Regional Bifurcation
9.2.11.5.1. North
America
9.2.11.5.1.1.
Market Estimation, 2015 - 2021
9.2.11.5.1.2.
Market Forecast, 2022 - 2030
9.2.11.5.2. Europe
9.2.11.5.2.1.
Market Estimation, 2015 - 2021
9.2.11.5.2.2.
Market Forecast, 2022 - 2030
9.2.11.5.3. Asia
Pacific
9.2.11.5.3.1.
Market Estimation, 2015 - 2021
9.2.11.5.3.2.
Market Forecast, 2022 - 2030
9.2.11.5.4. Middle
East and Africa
9.2.11.5.4.1.
Market Estimation, 2015 - 2021
9.2.11.5.4.2.
Market Forecast, 2022 - 2030
9.2.11.5.5. Latin
America
9.2.11.5.5.1.
Market Estimation, 2015 - 2021
9.2.11.5.5.2.
Market Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Treatment
10. North America Hypercholesterolemia Market Analysis and
Forecasts, 2022 - 2030
10.1. Overview
10.1.1. North
America Hypercholesterolemia Market Revenue (US$ Mn)
10.2. North
America Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
10.2.1. Blood
Tests
10.2.2. Cholesterol Tests
10.2.3. Genetic
Testing
10.2.4. Cardiac
stress test or an echocardiogram
10.3. North
America Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By
Treatment
10.3.1. Stains
10.3.2. Bile
acid sequestrant resins
10.3.3. Ezetimibe
10.3.4. Nicotinic
acid, or niacin
10.3.5. Gemfibrozil
10.3.6. Fenofibrate
10.3.7. Lovastatin
(Mevacor)
10.3.8. Pravastatin
(Pravachol)
10.3.9. Simvastatin (Zocor)
10.3.10. Fluvastatin
(Lescol)
10.3.11. Others
10.4. North
America Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By Country
10.4.1. U.S
10.4.1.1. U.S Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
10.4.1.1.1. Blood
Tests
10.4.1.1.2. Cholesterol Tests
10.4.1.1.3. Genetic
Testing
10.4.1.1.4. Cardiac
stress test or an echocardiogram
10.4.1.2. U.S Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
10.4.1.2.1. Stains
10.4.1.2.2. Bile
acid sequestrant resins
10.4.1.2.3. Ezetimibe
10.4.1.2.4. Nicotinic
acid, or niacin
10.4.1.2.5. Gemfibrozil
10.4.1.2.6. Fenofibrate
10.4.1.2.7. Lovastatin
(Mevacor)
10.4.1.2.8. Pravastatin
(Pravachol)
10.4.1.2.9. Simvastatin (Zocor)
10.4.1.2.10. Fluvastatin
(Lescol)
10.4.1.2.11. Others
10.4.2. Canada
10.4.2.1. Canada Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
10.4.2.1.1. Blood
Tests
10.4.2.1.2. Cholesterol Tests
10.4.2.1.3. Genetic
Testing
10.4.2.1.4. Cardiac
stress test or an echocardiogram
10.4.2.2. Canada Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
10.4.2.2.1. Stains
10.4.2.2.2. Bile
acid sequestrant resins
10.4.2.2.3. Ezetimibe
10.4.2.2.4. Nicotinic
acid, or niacin
10.4.2.2.5. Gemfibrozil
10.4.2.2.6. Fenofibrate
10.4.2.2.7. Lovastatin
(Mevacor)
10.4.2.2.8. Pravastatin
(Pravachol)
10.4.2.2.9. Simvastatin (Zocor)
10.4.2.2.10. Fluvastatin
(Lescol)
10.4.2.2.11. Others
10.4.3. Mexico
10.4.3.1. Mexico Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
10.4.3.1.1. Blood
Tests
10.4.3.1.2. Cholesterol Tests
10.4.3.1.3. Genetic
Testing
10.4.3.1.4. Cardiac
stress test or an echocardiogram
10.4.3.2. Mexico Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
10.4.3.2.1. Stains
10.4.3.2.2. Bile
acid sequestrant resins
10.4.3.2.3. Ezetimibe
10.4.3.2.4. Nicotinic
acid, or niacin
10.4.3.2.5. Gemfibrozil
10.4.3.2.6. Fenofibrate
10.4.3.2.7. Lovastatin
(Mevacor)
10.4.3.2.8. Pravastatin
(Pravachol)
10.4.3.2.9. Simvastatin (Zocor)
10.4.3.2.10. Fluvastatin
(Lescol)
10.4.3.2.11. Others
10.4.4. Rest of
North America
10.4.4.1. Rest of North America Hypercholesterolemia Market Revenue (US$
Mn) and Forecasts, By Diagnosis
10.4.4.1.1. Blood
Tests
10.4.4.1.2. Cholesterol Tests
10.4.4.1.3. Genetic
Testing
10.4.4.1.4. Cardiac
stress test or an echocardiogram
10.4.4.2. Rest of North America Hypercholesterolemia Market Revenue (US$
Mn) and Forecasts, By Treatment
10.4.4.2.1. Stains
10.4.4.2.2. Bile
acid sequestrant resins
10.4.4.2.3. Ezetimibe
10.4.4.2.4. Nicotinic
acid, or niacin
10.4.4.2.5. Gemfibrozil
10.4.4.2.6. Fenofibrate
10.4.4.2.7. Lovastatin
(Mevacor)
10.4.4.2.8. Pravastatin
(Pravachol)
10.4.4.2.9. Simvastatin (Zocor)
10.4.4.2.10. Fluvastatin
(Lescol)
10.4.4.2.11. Others
10.5. Key
Segment for Channeling Investments
10.5.1. By
Country
10.5.2. By
Diagnosis
10.5.3. By
Treatment
11. Europe Hypercholesterolemia Market Analysis and Forecasts, 2022
- 2030
11.1. Overview
11.1.1. Europe
Hypercholesterolemia Market Revenue (US$ Mn)
11.2. Europe
Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By Diagnosis
11.2.1. Blood
Tests
11.2.2. Cholesterol Tests
11.2.3. Genetic
Testing
11.2.4. Cardiac
stress test or an echocardiogram
11.3. Europe
Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By Treatment
11.3.1. Stains
11.3.2. Bile
acid sequestrant resins
11.3.3. Ezetimibe
11.3.4. Nicotinic
acid, or niacin
11.3.5. Gemfibrozil
11.3.6. Fenofibrate
11.3.7. Lovastatin
(Mevacor)
11.3.8. Pravastatin
(Pravachol)
11.3.9. Simvastatin (Zocor)
11.3.10. Fluvastatin
(Lescol)
11.3.11. Others
11.4. Europe
Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By Country
11.4.1. France
11.4.1.1. France Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
11.4.1.1.1. Blood
Tests
11.4.1.1.2. Cholesterol Tests
11.4.1.1.3. Genetic
Testing
11.4.1.1.4. Cardiac
stress test or an echocardiogram
11.4.1.2. France Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
11.4.1.2.1. Stains
11.4.1.2.2. Bile
acid sequestrant resins
11.4.1.2.3. Ezetimibe
11.4.1.2.4. Nicotinic
acid, or niacin
11.4.1.2.5. Gemfibrozil
11.4.1.2.6. Fenofibrate
11.4.1.2.7. Lovastatin
(Mevacor)
11.4.1.2.8. Pravastatin
(Pravachol)
11.4.1.2.9. Simvastatin (Zocor)
11.4.1.2.10. Fluvastatin
(Lescol)
11.4.1.2.11. Others
11.4.2. The UK
11.4.2.1. The UK Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
11.4.2.1.1. Blood
Tests
11.4.2.1.2. Cholesterol Tests
11.4.2.1.3. Genetic
Testing
11.4.2.1.4. Cardiac
stress test or an echocardiogram
11.4.2.2. The UK Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
11.4.2.2.1. Stains
11.4.2.2.2. Bile
acid sequestrant resins
11.4.2.2.3. Ezetimibe
11.4.2.2.4. Nicotinic
acid, or niacin
11.4.2.2.5. Gemfibrozil
11.4.2.2.6. Fenofibrate
11.4.2.2.7. Lovastatin
(Mevacor)
11.4.2.2.8. Pravastatin
(Pravachol)
11.4.2.2.9. Simvastatin (Zocor)
11.4.2.2.10. Fluvastatin
(Lescol)
11.4.2.2.11. Others
11.4.3. Spain
11.4.3.1. Spain Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
11.4.3.1.1. Blood
Tests
11.4.3.1.2. Cholesterol Tests
11.4.3.1.3. Genetic
Testing
11.4.3.1.4. Cardiac
stress test or an echocardiogram
11.4.3.2. Spain Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
11.4.3.2.1. Stains
11.4.3.2.2. Bile
acid sequestrant resins
11.4.3.2.3. Ezetimibe
11.4.3.2.4. Nicotinic
acid, or niacin
11.4.3.2.5. Gemfibrozil
11.4.3.2.6. Fenofibrate
11.4.3.2.7. Lovastatin
(Mevacor)
11.4.3.2.8. Pravastatin
(Pravachol)
11.4.3.2.9. Simvastatin (Zocor)
11.4.3.2.10. Fluvastatin
(Lescol)
11.4.3.2.11. Others
11.4.4. Germany
11.4.4.1. Germany Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
11.4.4.1.1. Blood
Tests
11.4.4.1.2. Cholesterol Tests
11.4.4.1.3. Genetic
Testing
11.4.4.1.4. Cardiac
stress test or an echocardiogram
11.4.4.2. Germany Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
11.4.4.2.1. Stains
11.4.4.2.2. Bile
acid sequestrant resins
11.4.4.2.3. Ezetimibe
11.4.4.2.4. Nicotinic
acid, or niacin
11.4.4.2.5. Gemfibrozil
11.4.4.2.6. Fenofibrate
11.4.4.2.7. Lovastatin
(Mevacor)
11.4.4.2.8. Pravastatin
(Pravachol)
11.4.4.2.9. Simvastatin (Zocor)
11.4.4.2.10. Fluvastatin
(Lescol)
11.4.4.2.11. Others
11.4.5. Italy
11.4.5.1. Italy Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
11.4.5.1.1. Blood
Tests
11.4.5.1.2. Cholesterol Tests
11.4.5.1.3. Genetic
Testing
11.4.5.1.4. Cardiac
stress test or an echocardiogram
11.4.5.2. Italy Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
11.4.5.2.1. Stains
11.4.5.2.2. Bile
acid sequestrant resins
11.4.5.2.3. Ezetimibe
11.4.5.2.4. Nicotinic
acid, or niacin
11.4.5.2.5. Gemfibrozil
11.4.5.2.6. Fenofibrate
11.4.5.2.7. Lovastatin
(Mevacor)
11.4.5.2.8. Pravastatin
(Pravachol)
11.4.5.2.9. Simvastatin (Zocor)
11.4.5.2.10. Fluvastatin
(Lescol)
11.4.5.2.11. Others
11.4.6. Nordic
Countries
11.4.6.1. Nordic Countries Hypercholesterolemia Market Revenue (US$ Mn)
and Forecasts, By Diagnosis
11.4.6.1.1. Blood
Tests
11.4.6.1.2. Cholesterol Tests
11.4.6.1.3. Genetic
Testing
11.4.6.1.4. Cardiac
stress test or an echocardiogram
11.4.6.2. Nordic Countries Hypercholesterolemia Market Revenue (US$ Mn)
and Forecasts, By Treatment
11.4.6.2.1. Stains
11.4.6.2.2. Bile
acid sequestrant resins
11.4.6.2.3. Ezetimibe
11.4.6.2.4. Nicotinic
acid, or niacin
11.4.6.2.5. Gemfibrozil
11.4.6.2.6. Fenofibrate
11.4.6.2.7. Lovastatin
(Mevacor)
11.4.6.2.8. Pravastatin
(Pravachol)
11.4.6.2.9. Simvastatin (Zocor)
11.4.6.2.10. Fluvastatin
(Lescol)
11.4.6.2.11. Others
11.4.6.3. Nordic Countries Hypercholesterolemia Market Revenue (US$ Mn)
and Forecasts, By Country
11.4.6.3.1. Denmark
11.4.6.3.2. Finland
11.4.6.3.3. Iceland
11.4.6.3.4. Sweden
11.4.6.3.5. Norway
11.4.7. Benelux
Union
11.4.7.1. Benelux Union Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
11.4.7.1.1. Blood
Tests
11.4.7.1.2. Cholesterol Tests
11.4.7.1.3. Genetic
Testing
11.4.7.1.4. Cardiac
stress test or an echocardiogram
11.4.7.2. Benelux Union Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
11.4.7.2.1. Stains
11.4.7.2.2. Bile
acid sequestrant resins
11.4.7.2.3. Ezetimibe
11.4.7.2.4. Nicotinic
acid, or niacin
11.4.7.2.5. Gemfibrozil
11.4.7.2.6. Fenofibrate
11.4.7.2.7. Lovastatin
(Mevacor)
11.4.7.2.8. Pravastatin
(Pravachol)
11.4.7.2.9. Simvastatin (Zocor)
11.4.7.2.10. Fluvastatin
(Lescol)
11.4.7.2.11. Others
11.4.7.3. Benelux Union Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Country
11.4.7.3.1. Belgium
11.4.7.3.2. The
Netherlands
11.4.7.3.3. Luxembourg
11.4.8. Rest of
Europe
11.4.8.1. Rest of Europe Hypercholesterolemia Market Revenue (US$ Mn)
and Forecasts, By Diagnosis
11.4.8.1.1. Blood
Tests
11.4.8.1.2. Cholesterol Tests
11.4.8.1.3. Genetic
Testing
11.4.8.1.4. Cardiac
stress test or an echocardiogram
11.4.8.2. Rest of Europe Hypercholesterolemia Market Revenue (US$ Mn)
and Forecasts, By Treatment
11.4.8.2.1. Stains
11.4.8.2.2. Bile
acid sequestrant resins
11.4.8.2.3. Ezetimibe
11.4.8.2.4. Nicotinic
acid, or niacin
11.4.8.2.5. Gemfibrozil
11.4.8.2.6. Fenofibrate
11.4.8.2.7. Lovastatin
(Mevacor)
11.4.8.2.8. Pravastatin
(Pravachol)
11.4.8.2.9. Simvastatin (Zocor)
11.4.8.2.10. Fluvastatin
(Lescol)
11.4.8.2.11. Others
11.5. Key
Segment for Channeling Investments
11.5.1. By
Country
11.5.2. By
Diagnosis
11.5.3. By
Treatment
12. Asia Pacific Hypercholesterolemia Market Analysis and
Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Asia
Pacific Hypercholesterolemia Market Revenue (US$ Mn)
12.2. Asia
Pacific Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.2.1. Blood
Tests
12.2.2. Cholesterol Tests
12.2.3. Genetic
Testing
12.2.4. Cardiac
stress test or an echocardiogram
12.3. Asia
Pacific Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By Treatment
12.3.1. Stains
12.3.2. Bile
acid sequestrant resins
12.3.3. Ezetimibe
12.3.4. Nicotinic
acid, or niacin
12.3.5. Gemfibrozil
12.3.6. Fenofibrate
12.3.7. Lovastatin
(Mevacor)
12.3.8. Pravastatin
(Pravachol)
12.3.9. Simvastatin (Zocor)
12.3.10. Fluvastatin
(Lescol)
12.3.11. Others
12.4. Asia
Pacific Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By Country
12.4.1. China
12.4.1.1. China Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
12.4.1.1.1. Blood
Tests
12.4.1.1.2. Cholesterol Tests
12.4.1.1.3. Genetic
Testing
12.4.1.1.4. Cardiac
stress test or an echocardiogram
12.4.1.2. China Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts,
By Treatment
12.4.1.2.1. Stains
12.4.1.2.2. Bile
acid sequestrant resins
12.4.1.2.3. Ezetimibe
12.4.1.2.4. Nicotinic
acid, or niacin
12.4.1.2.5. Gemfibrozil
12.4.1.2.6. Fenofibrate
12.4.1.2.7. Lovastatin
(Mevacor)
12.4.1.2.8. Pravastatin
(Pravachol)
12.4.1.2.9. Simvastatin (Zocor)
12.4.1.2.10. Fluvastatin
(Lescol)
12.4.1.2.11. Others
12.4.2. Japan
12.4.2.1. Japan Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
12.4.2.1.1. Blood
Tests
12.4.2.1.2. Cholesterol Tests
12.4.2.1.3. Genetic
Testing
12.4.2.1.4. Cardiac
stress test or an echocardiogram
12.4.2.2. Japan Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.4.2.2.1. Stains
12.4.2.2.2. Bile
acid sequestrant resins
12.4.2.2.3. Ezetimibe
12.4.2.2.4. Nicotinic
acid, or niacin
12.4.2.2.5. Gemfibrozil
12.4.2.2.6. Fenofibrate
12.4.2.2.7. Lovastatin
(Mevacor)
12.4.2.2.8. Pravastatin
(Pravachol)
12.4.2.2.9. Simvastatin (Zocor)
12.4.2.2.10. Fluvastatin
(Lescol)
12.4.2.2.11. Others
12.4.3. India
12.4.3.1. India Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
12.4.3.1.1. Blood
Tests
12.4.3.1.2. Cholesterol Tests
12.4.3.1.3. Genetic
Testing
12.4.3.1.4. Cardiac
stress test or an echocardiogram
12.4.3.2. India Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.4.3.2.1. Stains
12.4.3.2.2. Bile
acid sequestrant resins
12.4.3.2.3. Ezetimibe
12.4.3.2.4. Nicotinic
acid, or niacin
12.4.3.2.5. Gemfibrozil
12.4.3.2.6. Fenofibrate
12.4.3.2.7. Lovastatin
(Mevacor)
12.4.3.2.8. Pravastatin
(Pravachol)
12.4.3.2.9. Simvastatin (Zocor)
12.4.3.2.10. Fluvastatin
(Lescol)
12.4.3.2.11. Others
12.4.4. New
Zealand
12.4.4.1. New Zealand Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
12.4.4.1.1. Blood
Tests
12.4.4.1.2. Cholesterol Tests
12.4.4.1.3. Genetic
Testing
12.4.4.1.4. Cardiac
stress test or an echocardiogram
12.4.4.2. New Zealand Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.4.4.2.1. Stains
12.4.4.2.2. Bile
acid sequestrant resins
12.4.4.2.3. Ezetimibe
12.4.4.2.4. Nicotinic
acid, or niacin
12.4.4.2.5. Gemfibrozil
12.4.4.2.6. Fenofibrate
12.4.4.2.7. Lovastatin
(Mevacor)
12.4.4.2.8. Pravastatin
(Pravachol)
12.4.4.2.9. Simvastatin (Zocor)
12.4.4.2.10. Fluvastatin
(Lescol)
12.4.4.2.11. Others
12.4.5. Australia
12.4.5.1. Australia Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
12.4.5.1.1. Blood
Tests
12.4.5.1.2. Cholesterol Tests
12.4.5.1.3. Genetic
Testing
12.4.5.1.4. Cardiac
stress test or an echocardiogram
12.4.5.2. Australia Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.4.5.2.1. Stains
12.4.5.2.2. Bile
acid sequestrant resins
12.4.5.2.3. Ezetimibe
12.4.5.2.4. Nicotinic
acid, or niacin
12.4.5.2.5. Gemfibrozil
12.4.5.2.6. Fenofibrate
12.4.5.2.7. Lovastatin
(Mevacor)
12.4.5.2.8. Pravastatin
(Pravachol)
12.4.5.2.9. Simvastatin (Zocor)
12.4.5.2.10. Fluvastatin
(Lescol)
12.4.5.2.11. Others
12.4.6. South
Korea
12.4.6.1. South Korea Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
12.4.6.1.1. Blood
Tests
12.4.6.1.2. Cholesterol Tests
12.4.6.1.3. Genetic
Testing
12.4.6.1.4. Cardiac
stress test or an echocardiogram
12.4.6.2. South Korea Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.4.6.2.1. Stains
12.4.6.2.2. Bile
acid sequestrant resins
12.4.6.2.3. Ezetimibe
12.4.6.2.4. Nicotinic
acid, or niacin
12.4.6.2.5. Gemfibrozil
12.4.6.2.6. Fenofibrate
12.4.6.2.7. Lovastatin
(Mevacor)
12.4.6.2.8. Pravastatin
(Pravachol)
12.4.6.2.9. Simvastatin (Zocor)
12.4.6.2.10. Fluvastatin
(Lescol)
12.4.6.2.11. Others
12.4.7. Southeast
Asia
12.4.7.1. Southeast Asia Hypercholesterolemia Market Revenue (US$ Mn)
and Forecasts, By Diagnosis
12.4.7.1.1. Blood
Tests
12.4.7.1.2. Cholesterol Tests
12.4.7.1.3. Genetic
Testing
12.4.7.1.4. Cardiac
stress test or an echocardiogram
12.4.7.2. Southeast Asia Hypercholesterolemia Market Revenue (US$ Mn)
and Forecasts, By Treatment
12.4.7.2.1. Stains
12.4.7.2.2. Bile
acid sequestrant resins
12.4.7.2.3. Ezetimibe
12.4.7.2.4. Nicotinic
acid, or niacin
12.4.7.2.5. Gemfibrozil
12.4.7.2.6. Fenofibrate
12.4.7.2.7. Lovastatin
(Mevacor)
12.4.7.2.8. Pravastatin
(Pravachol)
12.4.7.2.9. Simvastatin (Zocor)
12.4.7.2.10. Fluvastatin
(Lescol)
12.4.7.2.11. Others
12.4.7.3. Southeast Asia Hypercholesterolemia Market Revenue (US$ Mn)
and Forecasts, By Country
12.4.7.3.1. Indonesia
12.4.7.3.2. Thailand
12.4.7.3.3. Malaysia
12.4.7.3.4. Singapore
12.4.7.3.5. Rest
of Southeast Asia
12.4.8. Rest of
Asia Pacific
12.4.8.1. Rest of Asia Pacific Hypercholesterolemia Market Revenue (US$
Mn) and Forecasts, By Diagnosis
12.4.8.1.1. Blood
Tests
12.4.8.1.2. Cholesterol Tests
12.4.8.1.3. Genetic
Testing
12.4.8.1.4. Cardiac
stress test or an echocardiogram
12.4.8.2. Rest of Asia Pacific Hypercholesterolemia Market Revenue (US$
Mn) and Forecasts, By Treatment
12.4.8.2.1. Stains
12.4.8.2.2. Bile
acid sequestrant resins
12.4.8.2.3. Ezetimibe
12.4.8.2.4. Nicotinic
acid, or niacin
12.4.8.2.5. Gemfibrozil
12.4.8.2.6. Fenofibrate
12.4.8.2.7. Lovastatin
(Mevacor)
12.4.8.2.8. Pravastatin
(Pravachol)
12.4.8.2.9. Simvastatin (Zocor)
12.4.8.2.10. Fluvastatin
(Lescol)
12.4.8.2.11. Others
12.5. Key
Segment for Channeling Investments
12.5.1. By
Country
12.5.2. By
Diagnosis
12.5.3. By
Treatment
13. Middle East and Africa Hypercholesterolemia Market Analysis
and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Middle
East and Africa Hypercholesterolemia Market Revenue (US$ Mn)
13.2. Middle
East and Africa Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.2.1. Blood
Tests
13.2.2. Cholesterol Tests
13.2.3. Genetic
Testing
13.2.4. Cardiac
stress test or an echocardiogram
13.3. Middle
East and Africa Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By
Treatment
13.3.1. Stains
13.3.2. Bile
acid sequestrant resins
13.3.3. Ezetimibe
13.3.4. Nicotinic
acid, or niacin
13.3.5. Gemfibrozil
13.3.6. Fenofibrate
13.3.7. Lovastatin
(Mevacor)
13.3.8. Pravastatin
(Pravachol)
13.3.9. Simvastatin (Zocor)
13.3.10. Fluvastatin
(Lescol)
13.3.11. Others
13.4. Middle
East and Africa Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By
Country
13.4.1. Saudi
Arabia
13.4.1.1. Saudi Arabia Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.4.1.1.1. Blood
Tests
13.4.1.1.2. Cholesterol Tests
13.4.1.1.3. Genetic
Testing
13.4.1.1.4. Cardiac
stress test or an echocardiogram
13.4.1.2. Saudi Arabia Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.4.1.2.1. Stains
13.4.1.2.2. Bile
acid sequestrant resins
13.4.1.2.3. Ezetimibe
13.4.1.2.4. Nicotinic
acid, or niacin
13.4.1.2.5. Gemfibrozil
13.4.1.2.6. Fenofibrate
13.4.1.2.7. Lovastatin
(Mevacor)
13.4.1.2.8. Pravastatin
(Pravachol)
13.4.1.2.9. Simvastatin (Zocor)
13.4.1.2.10. Fluvastatin
(Lescol)
13.4.1.2.11. Others
13.4.2. UAE
13.4.2.1. UAE Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.4.2.1.1. Blood
Tests
13.4.2.1.2. Cholesterol Tests
13.4.2.1.3. Genetic
Testing
13.4.2.1.4. Cardiac
stress test or an echocardiogram
13.4.2.2. UAE Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.4.2.2.1. Stains
13.4.2.2.2. Bile
acid sequestrant resins
13.4.2.2.3. Ezetimibe
13.4.2.2.4. Nicotinic
acid, or niacin
13.4.2.2.5. Gemfibrozil
13.4.2.2.6. Fenofibrate
13.4.2.2.7. Lovastatin
(Mevacor)
13.4.2.2.8. Pravastatin
(Pravachol)
13.4.2.2.9. Simvastatin (Zocor)
13.4.2.2.10. Fluvastatin
(Lescol)
13.4.2.2.11. Others
13.4.3. Egypt
13.4.3.1. Egypt Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.4.3.1.1. Blood
Tests
13.4.3.1.2. Cholesterol Tests
13.4.3.1.3. Genetic
Testing
13.4.3.1.4. Cardiac
stress test or an echocardiogram
13.4.3.2. Egypt Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.4.3.2.1. Stains
13.4.3.2.2. Bile
acid sequestrant resins
13.4.3.2.3. Ezetimibe
13.4.3.2.4. Nicotinic
acid, or niacin
13.4.3.2.5. Gemfibrozil
13.4.3.2.6. Fenofibrate
13.4.3.2.7. Lovastatin
(Mevacor)
13.4.3.2.8. Pravastatin
(Pravachol)
13.4.3.2.9. Simvastatin (Zocor)
13.4.3.2.10. Fluvastatin
(Lescol)
13.4.3.2.11. Others
13.4.4. Kuwait
13.4.4.1. Kuwait Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.4.4.1.1. Blood
Tests
13.4.4.1.2. Cholesterol Tests
13.4.4.1.3. Genetic
Testing
13.4.4.1.4. Cardiac
stress test or an echocardiogram
13.4.4.2. Kuwait Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.4.4.2.1. Stains
13.4.4.2.2. Bile
acid sequestrant resins
13.4.4.2.3. Ezetimibe
13.4.4.2.4. Nicotinic
acid, or niacin
13.4.4.2.5. Gemfibrozil
13.4.4.2.6. Fenofibrate
13.4.4.2.7. Lovastatin
(Mevacor)
13.4.4.2.8. Pravastatin
(Pravachol)
13.4.4.2.9. Simvastatin (Zocor)
13.4.4.2.10. Fluvastatin
(Lescol)
13.4.4.2.11. Others
13.4.5. South
Africa
13.4.5.1. South Africa Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
13.4.5.1.1. Blood
Tests
13.4.5.1.2. Cholesterol Tests
13.4.5.1.3. Genetic
Testing
13.4.5.1.4. Cardiac
stress test or an echocardiogram
13.4.5.2. South Africa Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.4.5.2.1. Stains
13.4.5.2.2. Bile
acid sequestrant resins
13.4.5.2.3. Ezetimibe
13.4.5.2.4. Nicotinic
acid, or niacin
13.4.5.2.5. Gemfibrozil
13.4.5.2.6. Fenofibrate
13.4.5.2.7. Lovastatin
(Mevacor)
13.4.5.2.8. Pravastatin
(Pravachol)
13.4.5.2.9. Simvastatin (Zocor)
13.4.5.2.10. Fluvastatin
(Lescol)
13.4.5.2.11. Others
13.4.6. Rest of
Middle East & Africa
13.4.6.1. Rest of Middle East & Africa Hypercholesterolemia Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
13.4.6.1.1. Blood
Tests
13.4.6.1.2. Cholesterol Tests
13.4.6.1.3. Genetic
Testing
13.4.6.1.4. Cardiac
stress test or an echocardiogram
13.4.6.2. Rest of Middle East & Africa Hypercholesterolemia Market
Revenue (US$ Mn) and Forecasts, By Treatment
13.4.6.2.1. Stains
13.4.6.2.2. Bile
acid sequestrant resins
13.4.6.2.3. Ezetimibe
13.4.6.2.4. Nicotinic
acid, or niacin
13.4.6.2.5. Gemfibrozil
13.4.6.2.6. Fenofibrate
13.4.6.2.7. Lovastatin
(Mevacor)
13.4.6.2.8. Pravastatin
(Pravachol)
13.4.6.2.9. Simvastatin (Zocor)
13.4.6.2.10. Fluvastatin
(Lescol)
13.4.6.2.11. Others
13.5. Key
Segment for Channeling Investments
13.5.1. By
Country
13.5.2. By
Diagnosis
13.5.3. By
Treatment
14. Latin America Hypercholesterolemia Market Analysis and
Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Latin
America Hypercholesterolemia Market Revenue (US$ Mn)
14.2. Latin
America Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.2.1. Blood
Tests
14.2.2. Cholesterol Tests
14.2.3. Genetic
Testing
14.2.4. Cardiac
stress test or an echocardiogram
14.3. Latin
America Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.3.1. Stains
14.3.2. Bile
acid sequestrant resins
14.3.3. Ezetimibe
14.3.4. Nicotinic
acid, or niacin
14.3.5. Gemfibrozil
14.3.6. Fenofibrate
14.3.7. Lovastatin
(Mevacor)
14.3.8. Pravastatin
(Pravachol)
14.3.9. Simvastatin (Zocor)
14.3.10. Fluvastatin
(Lescol)
14.3.11. Others
14.4. Latin
America Hypercholesterolemia Market Revenue (US$ Mn) and Forecasts, By Country
14.4.1. Brazil
14.4.1.1. Brazil Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
14.4.1.1.1. Blood
Tests
14.4.1.1.2. Cholesterol Tests
14.4.1.1.3. Genetic
Testing
14.4.1.1.4. Cardiac
stress test or an echocardiogram
14.4.1.2. Brazil Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.4.1.2.1. Stains
14.4.1.2.2. Bile
acid sequestrant resins
14.4.1.2.3. Ezetimibe
14.4.1.2.4. Nicotinic
acid, or niacin
14.4.1.2.5. Gemfibrozil
14.4.1.2.6. Fenofibrate
14.4.1.2.7. Lovastatin
(Mevacor)
14.4.1.2.8. Pravastatin
(Pravachol)
14.4.1.2.9. Simvastatin (Zocor)
14.4.1.2.10. Fluvastatin
(Lescol)
14.4.1.2.11. Others
14.4.2. Argentina
14.4.2.1. Argentina Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
14.4.2.1.1. Blood
Tests
14.4.2.1.2. Cholesterol Tests
14.4.2.1.3. Genetic
Testing
14.4.2.1.4. Cardiac
stress test or an echocardiogram
14.4.2.2. Argentina Hypercholesterolemia Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.4.2.2.1. Stains
14.4.2.2.2. Bile
acid sequestrant resins
14.4.2.2.3. Ezetimibe
14.4.2.2.4. Nicotinic
acid, or niacin
14.4.2.2.5. Gemfibrozil
14.4.2.2.6. Fenofibrate
14.4.2.2.7. Lovastatin
(Mevacor)
14.4.2.2.8. Pravastatin
(Pravachol)
14.4.2.2.9. Simvastatin (Zocor)
14.4.2.2.10. Fluvastatin
(Lescol)
14.4.2.2.11. Others
14.4.3. Rest of
Latin America
14.4.3.1. Rest of Latin America Hypercholesterolemia Market Revenue (US$
Mn) and Forecasts, By Diagnosis
14.4.3.1.1. Blood
Tests
14.4.3.1.2. Cholesterol Tests
14.4.3.1.3. Genetic
Testing
14.4.3.1.4. Cardiac
stress test or an echocardiogram
14.4.3.2. Rest of Latin America Hypercholesterolemia Market Revenue (US$
Mn) and Forecasts, By Treatment
14.4.3.2.1. Stains
14.4.3.2.2. Bile
acid sequestrant resins
14.4.3.2.3. Ezetimibe
14.4.3.2.4. Nicotinic
acid, or niacin
14.4.3.2.5. Gemfibrozil
14.4.3.2.6. Fenofibrate
14.4.3.2.7. Lovastatin
(Mevacor)
14.4.3.2.8. Pravastatin
(Pravachol)
14.4.3.2.9. Simvastatin (Zocor)
14.4.3.2.10. Fluvastatin
(Lescol)
14.4.3.2.11. Others
14.5. Key
Segment for Channeling Investments
14.5.1. By
Country
14.5.2. By
Diagnosis
14.5.3. By
Treatment
15. Competitive Benchmarking
15.1. Brand
Benchmarking
15.2. Market
Share Analysis, 2021
15.3. Global
Presence and Growth Strategies
15.3.1. Mergers
and Acquisitions
15.3.2. Product
Launches
15.3.3. Investments
Trends
15.3.4. R&D
Initiatives
16. Player Profiles
16.1. Aegerion
Pharmaceuticals, Inc.
16.1.1. Company
Details
16.1.2. Company
Overview
16.1.3. Product
Offerings
16.1.4. Key
Developments
16.1.5. Financial
Analysis
16.1.6. SWOT
Analysis
16.1.7. Business
Strategies
16.2. Alnylam Pharmaceuticals, Inc.
16.2.1. Company
Details
16.2.2. Company
Overview
16.2.3. Product
Offerings
16.2.4. Key
Developments
16.2.5. Financial
Analysis
16.2.6. SWOT
Analysis
16.2.7. Business
Strategies
16.3. Amarin Pharmaceuticals, Inc.
16.3.1. Company
Details
16.3.2. Company
Overview
16.3.3. Product
Offerings
16.3.4. Key
Developments
16.3.5. Financial
Analysis
16.3.6. SWOT
Analysis
16.3.7. Business
Strategies
16.4. Amgen Inc.
16.4.1. Company
Details
16.4.2. Company
Overview
16.4.3. Product
Offerings
16.4.4. Key
Developments
16.4.5. Financial
Analysis
16.4.6. SWOT
Analysis
16.4.7. Business
Strategies
16.5. AstraZeneca
16.5.1. Company
Details
16.5.2. Company
Overview
16.5.3. Product
Offerings
16.5.4. Key
Developments
16.5.5. Financial
Analysis
16.5.6. SWOT
Analysis
16.5.7. Business
Strategies
16.6. Eli Lily and Company
16.6.1. Company
Details
16.6.2. Company
Overview
16.6.3. Product
Offerings
16.6.4. Key
Developments
16.6.5. Financial
Analysis
16.6.6. SWOT
Analysis
16.6.7. Business
Strategies
16.7. Novartis AG
16.7.1. Company
Details
16.7.2. Company
Overview
16.7.3. Product
Offerings
16.7.4. Key
Developments
16.7.5. Financial
Analysis
16.7.6. SWOT
Analysis
16.7.7. Business
Strategies
16.8. Regeneron Pharmaceuticals, Inc.
16.8.1. Company
Details
16.8.2. Company
Overview
16.8.3. Product
Offerings
16.8.4. Key
Developments
16.8.5. Financial
Analysis
16.8.6. SWOT
Analysis
16.8.7. Business
Strategies
16.9. Sanofi
16.9.1. Company
Details
16.9.2. Company
Overview
16.9.3. Product
Offerings
16.9.4. Key
Developments
16.9.5. Financial
Analysis
16.9.6. SWOT
Analysis
16.9.7. Business
Strategies
16.10. Tekmira Pharmaceuticals Corporation
16.10.1. Company
Details
16.10.2. Company
Overview
16.10.3. Product
Offerings
16.10.4. Key
Developments
16.10.5. Financial
Analysis
16.10.6. SWOT
Analysis
16.10.7. Business
Strategies
16.11. Valbiotis
16.11.1. Company
Details
16.11.2. Company
Overview
16.11.3. Product
Offerings
16.11.4. Key
Developments
16.11.5. Financial
Analysis
16.11.6. SWOT
Analysis
16.11.7. Business
Strategies
16.12. Verve Therapeutics, Inc.
16.12.1.
Company Details
16.12.2.
Company Overview
16.12.3.
Product Offerings
16.12.4.
Key Developments
16.12.5.
Financial Analysis
16.12.6.
SWOT Analysis
16.12.7.
Business Strategies
16.13. Other Market
Participants
17. Key Findings
Note: This ToC is tentative and can be changed according to the research
study conducted during the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.